Teneligliptin

• CAS: 906093-29-6
• Catalog Number: ACM906093296
• Category: Main Products
• Molecular Weight: 0
• Molecular Formula: 2(C₂₂H₃₀N₆OS).5(HBr)
• Synonyms: Teneligliptin (hydrobroMide);Teneligliptin HydrobroMide Hydrate;3-[[(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl]carbonyl]-thiazolidine hydrobromide (2:5);Teneligliptin HydrobroMide (2:5);Teneligliptin HBr
• IUPAC Name: [(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone;pentahydrobromide
• Canonical SMILES: CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5.CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5.Br.Br.Br.Br.Br
• InChI Key: LUXIOMHUGCXFIU-MAYGPZJUSA-N
• Appearance: off-white to brown solid
• Exact Mass: 1252.07000

Case Study

Teneligliptin in Combination with Canagliflozin for Enhanced Body Weight and Lipid Metabolism Management in Type 2 Diabetes Mellitus

Kawarasaki S, et al. European Journal of Pharmacology, 2023, 947, 175682.

In a study involving high-fat diet (HFD)-induced obese mice, teneligliptin, when used as monotherapy or in combination with the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin, showed significant effects on body weight reduction and lipid metabolism. The combination therapy further enhanced the suppressive effect on body weight gain and inguinal white adipose tissue (iWAT) mass compared to monotherapies, suggesting a synergistic effect. Notably, the combined treatment improved oxygen consumption, indicating increased metabolic activity, without altering thermogenesis-related gene expression in adipose tissue. Furthermore, it tended to upregulate fatty acid oxidation genes in brown adipose tissue and downregulate fatty acid synthesis genes in iWAT and liver tissues, indicating a shift towards enhanced lipid metabolism. These findings support the application of teneligliptin, particularly in combination with SGLT2 inhibitors like canagliflozin, as an effective therapeutic strategy for managing body weight and lipid disorders in Type 2 diabetes mellitus (T2DM) patients, especially those with concurrent obesity.

Teneligliptin in Combination with Metformin and Glimepiride for Enhanced Glycemic Control and Insulin Resistance Management in Type 2 Diabetes Mellitus

Manchi R. K, et al. Current Diabetes Reviews, 2025, 21(6).

In a clinical trial involving 300 adult T2DM patients, the combination of teneligliptin with metformin and glimepiride (triple-drug therapy) demonstrated marked improvements in key metabolic parameters. After 12 months of treatment, the triple-drug regimen significantly reduced HbA1c, fasting blood sugar (FBS), postprandial blood sugar (PPBS), fasting insulin, and C-peptide levels, while improving insulin resistance as measured by HOMA-IR. Moreover, the therapy had positive effects on lipid profiles, further supporting its comprehensive impact on metabolic health. Importantly, no serious adverse effects, including hypoglycemia, were reported, underscoring the safety of this combination therapy. These findings highlight teneligliptin's role in enhancing the therapeutic efficacy of other antidiabetic agents and its potential for improving both glycemic control and insulin sensitivity in Type 2 Diabetes Mellitus (T2DM) patients, with favorable effects on lipid and organ profiles.